Edward G. Neilan from NORD discusses critical efforts to speed up therapy development for rare diseases lacking treatments ...
Island Pharmaceuticals’ March quarterly update highlights considerable progress advancing the clinical development pathway ...
- Publication in Human Gene Therapy provides rationale for the use of microdystrophin expression levels as a surrogate endpoint reasonably likely to predict clinical benefit for AAV gene therapy ...
Dynamic clinical pathways are essential to keep pace with rapid advancements in oncology treatments and FDA approvals. Inclusive participation and effective communication are vital for pathway ...
The FDA has granted Priority Review of Celcuity’s New Drug Application (“NDA”) for gedatolisib in patients with HR+/HER2-/ PIK3CA wild-type (“WT”) ABC and assigned a Prescription Drug User Fee Act ...
Ryan Haumschild, PharmD, MS, MBA, drives an expert discussion focused on challenges associated with clinical pathway utilization in treating patients with HCC. The panel discussion focused on the ...
4P004 is a GLP-1 analog specifically engineered for intra-articular administration in the knee. It is designed to leverage the pleiotropic properties of GLP-1, including analgesic, anti-inflammatory, ...
Expanding the Multidisciplinary Team in Prediagnostic Care of Lung Cancer: How Else Can We Improve Time to Targeted Treatment in Metastatic Non–Small-Cell Lung Cancer? In the article that accompanies ...
Phase II Clinical Study of Adebrelimab and Bevacizumab Combined With Cisplatin/Carboplatin in Patients With Triple-Negative Breast Cancer With Brain Metastases (ABC Study) Receipt of previous ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results